Clinical Trial Search

Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes

Primary: Posterior Capsule Opacification (PCO) — 3.0; 1.9 units on a scale (0-10)

Primary: Posterior Capsule Opacification (PCO) — 11.58; 14.04 Percentage of PCO

Primary: Changes of Foveal and Pericentral Pigment Optical Density (Log Unit) From Baseline at 2 Months — 0.55; 0.52; 0.51; 0.5 log unit — p=<0.01

Primary: Low Contrast Best Corrected Visual Acuity Following Cataract Surgery — 0.22; 0.24 LogMAR

Primary: Effective Lens Position — 3.97; 4.02; 3.93; 3.99 mm

Primary: Posterior Capsule Opacification (PCO) — 0.18; 0.15 Units on a scale

Primary: Mean Difference Between Predicted and Actual Central Vault at 1-month After ICL Implantation — 0.170 Milimeters

Primary: Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy — 15 Participants

Primary: Percentage of Participants With Lens Opacification Event Development or Progression by Month 12 — 33.2; 33.5 percentage of participants — p=0.0026

Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal

Primary: Visual Acuity — 108 Participants

Primary: Number of Participants Who Have Spectacle Independence — 27 Participants

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at the Long-Term, Post-Implantation Visit — -0.06; -0.09; -0.07; 0.01 logMAR

Primary: Number of Subjects Reporting Spatial Distortions Related to Intraocular Lens (IOL) Misalignment — 11; 2 Participants

Primary: Tilt of the PCIOL and IOPCL MAG Complex — 9; 9 Eyes

Primary: Number of Subjects With Absence of Anterior Chamber Cells (i.e. Score of '0') — 26; 34; 10 participants

Primary: Preoperative and Postoperative Intraocular Pressure — 20.1; 9 mm Hg — p=0.01

Primary: Number of Participants With an Absence of Anterior Chamber Inflammation — 63; 25 participants

Primary: Absence of Anterior Chamber Inflammation — 52.3; 31.1 percentage of total participants

Primary: Change in Humphrey Visual Fields - Total Sensitivity — 1.4; 16.8; -164.8; -66.7 dB

Primary: Central Endothelial Cell Density (All Eyes) — 2654.0; 2639.0; 2633.0; 2551.0 cells/mm^2

Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct

Primary: The Primary Outcome is the Change in Best-corrected Visual Acuity (BCVA) Using the Electronic Visual Acuity (EVA) Technology at Month 12. — 1; 1; 3; 1 participants

Primary: Patient Satisfaction — 5.37; 5.23; 5.37; 5.05 score on a scale — p=<0.05

Primary: Visual Acuity at Distance (6m) logMAR — 0.00; -0.02; 0.02; 0.00 logMAR

Primary: Subjects With Stable Manifest Refraction Spherical Equivalent (MRSE) — 7 Subjects

Primary: Percentage of Capsular Tears (Anterior or Posterior) During Surgery — 5.3; 5.3 percentage of capsular tears

Primary: Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration — 5.57 ng/mL

Primary: Mean Percent Cell Change (Preservation of Endothelium) — -10.05; -10.13 percent cell change